ZOM has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
ZOM has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Zomedica's EPS without NRI for the three months ended in Dec. 2023 was $-0.01.
During the past 3 years, the average EPS without NRI Growth Rate was 21.20% per year. During the past 5 years, the average EPS without NRI Growth Rate was 38.90% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.
During the past 11 years, the highest 3-Year average EPS without NRI Growth Rate of Zomedica was 55.30% per year. The lowest was -123.70% per year. And the median was 19.75% per year.
For the Medical Devices subindustry, Zomedica's 3-Year EPS without NRI Growth Rate, along with its competitors' market caps and 3-Year EPS without NRI Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Medical Devices & Instruments industry and Healthcare sector, Zomedica's 3-Year EPS without NRI Growth Rate distribution charts can be found below:
* The bar in red indicates where Zomedica's 3-Year EPS without NRI Growth Rate falls into.
This is the 3-year average growth rate of EPS without NRI. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.
Zomedica (AMEX:ZOM) 3-Year EPS without NRI Growth Rate Explanation
EPS without NRI is the amount of earnings without non-recurring items per outstanding share of the company's stock.
Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists Earnings per share without Non-Recurring Items, which better reflects the company's underlying performance.
Thank you for viewing the detailed overview of Zomedica's 3-Year EPS without NRI Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.
Johnny D Powers | director | C/O ZOMEDICA CORP., 100 PHOENIX DRIVE, SUITE 125, ANN ARBOR MI 48018 |
Heaton Larry C Ii | officer: President | C/O ZOMEDICA CORP., 100 PHOENIX DRIVE, SUITE 125, ANN ARBOR MI 48018 |
Russell Kevin Klass | officer: Vice President of Sales | C/O ZOMEDICA CORP, PHOENIX DRIVE, SUITE 125, ANN ARBOR MI 48108 |
Peter Donato | officer: Chief Financial Officer | 9172 ETON AVENUE, CHATSWORTH CA 91311 |
Pamela Nichols | director | 14841 EAST WILDCAT DR., SCOTTSDALE AZ 85262 |
Karen Dehaan-fullerton | officer: Chief Counsel and Secretary | C/O ZOMEDICA CORP, 100 PHOENIX DRIVE, SUITE 125, ANN ARBOR MI 48018 |
Anthony K Blair | officer: Chief Operating Officer | NEOPROBE CORPORATION, 425 METRO PLACE NORTH #300, DUBLIN OH 43017 |
Adrian Lock | officer: VP and General Manager | C/O ZOMEDICA CORP, 100 PHOENIX DRIVE, SUITE 125, ANN ARBOR MI 48018 |
Sean Whelan | director | C/O ZOMEDICA CORP., 100 PHOENIX DRIVE, SUITE 125, ANN ARBOR MI 48108 |
Robert Cohen | officer: Interim CEO | C/O ZOMEDICA CORP., 100 PHOENIX DRIVE, SUITE 125, ANN ARBOR MI 48108 |
Ann Cotter | officer: Chief Financial Officer & Sec. | C/O ZOMEDICA PHARMACEUTICALS CORP., 100 PHOENIX DRIVE, SUITE 180, ANN ARBOR MI 48108 |
Stephanie Morley | officer: COO & VP of Product Dev | C/O ZOMEDICA CORP., 100 PHOENIX DRIVE, SUITE 125, ANN ARBOR MI 48108 |
Christopher Ross Macleod | director | C/O ZOMEDICA CORP., 100 PHOENIX DRIVE, SUITE 125, ANN ARBOR MI 48018 |
Christopher Wolfenberg | director | C/O ZOMEDICA PHARMACEUTICALS CORP, 100 PHOENIX DRIVE, SUITE 180, ANN ARBOR MI 48108 |
Gerald Jr Solensky | director, 10 percent owner, officer: President and CEO | C/O ZOMEDICA PHARMACEUTICALS CORP., 100 PHOENIX DRIVE, SUITE 190, ANN ARBOR MI 48108 |
From GuruFocus
By ACCESSWIRE • 11-28-2023
By ACCESSWIRE • 09-14-2023
By ACCESSWIRE • 09-01-2023
By ACCESSWIRE • 12-18-2023
By ACCESSWIRE ACCESSWIRE • 03-31-2023
By ACCESSWIRE • 08-31-2023
By ACCESSWIRE • 10-11-2023
By ACCESSWIRE • 01-18-2024
By ACCESSWIRE • 12-06-2023
By ACCESSWIRE ACCESSWIRE • 05-12-2023
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.